For immediate release 7.00am: 23 September 2016
("hVIVO" or the "Company")
Exercise of Share Options
hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, announces that, following the exercise of employee share options, application has been made to AIM for the admission of 10,125 new ordinary shares of 5.0p each (the "New Ordinary Shares").
Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 78,090,310 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 28 September 2016.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three First-In-Class therapies currently in development with a growing pre-clinical pipeline.
This information is provided by RNS